American Association for Cancer Research

Program

AACR-IASLC Joint Lung Cancer Conference 2014

Program as of December 26; subject to change

Monday, January 6

Opening Keynote Session

Session Co-Chairpersons: Elisabeth M. P. Brambilla, INSERM U823 - CHU Grenoble, Grenoble, France, and Roy S. Herbst, Yale Cancer Center, New Haven, CT
6:00 p.m.-7:30 p.m.

Welcome Remarks
Roy S. Herbst and Elisabeth M. P. Brambilla

Keynote Address: Immunotherapy
Immunology of anti-PD-1/PD-L1 therapy in lung cancer
Lieping Chen, Yale University School of Medicine, New Haven, CT 

Keynote Discussion

Perspective
Kim Norris, Lung Cancer Foundation of America, Los Angeles, CA

Welcome Reception

7:30 p.m.-9:00 p.m.

 

Tuesday, January 7

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 1: New Findings in Small Cell Lung Cancer

Session Co-Chairpersons: Paul A. Bunn, Jr., University of Colorado Denver, Aurora, CO, and John D. Minna, UT Southwestern Medical Center, Dallas, TX
8:00 a.m.-10:00 a.m.

A drug-repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer
Julien Sage, Stanford University School of Medicine, Stanford, CA

Genomic and epigenomic targets in small cell lung cancer
Charles M. Rudin, Memorial Sloan-Kettering Cancer Center, New York, NY

Decoding the genomic architecture of small cell lung cancer
Julie George, University of Cologne, Cologne, Germany

Mouse models cancer: Heterogeneity and cell-of-origin of small cell and non-small cell lung cancer
Anton J. M. Berns, Netherlands Cancer Institute, Amsterdam, The Netherlands

Break

10:00 a.m.-10:30 a.m.

Plenary Session 2: Clinical Trial Design and Master Protocols

Session Co-Chairpersons: William C. Timmer, National Cancer Institute, Bethesda, MD, and David Gandara, UC Davis Comprehensive Cancer Center, Sacramento, CA
10:30 a.m.-12:30 p.m.

Innovative clinical trial designs for NSCLC: From BATTLE to master protocols
Roy S. Herbst, Yale Cancer Center, New Haven, CT

Adaptive designs and adaptive learning for biomarker-based clinical trials for targeted therapies
J. Jack Lee, The University of Texas MD Anderson Cancer Center, Houston, TX

Biomarkers and the master protocol
Fred R. Hirsch, University of Colorado School of Medicine, Aurora, CO 

Clinical trial design and master protocols in NCI clinical treatment trials
Margaret Mooney, National Cancer Institute, Bethesda, MD

Poster Session A / Lunch

12:30 p.m.-2:30 p.m.

Concurrent Sessions 1-2

2:30 p.m.-4:30 p.m.

  • Concurrent Session 1: Pathology and Pathogenesis
    Session Co-Chairpersons: Elisabeth M. P. Brambilla, INSERM U823 - CHU Grenoble, Grenoble, France, and Ming-Sound Tsao, University of Toronto University Health Network, Toronto, ON, Canada
    • Squamous cell carcinoma: Pathology, etiology, and molecular drivers
      Elisabeth M. P. Brambilla
    • Molecular testing to personalize EGFR and ALK inhibitor therapies in lung cancer
      Ming-Sound Tsao
    • Challenges and promises of applying molecular profiles for lung cancer treatment and early diagnosis
      Ignacio I. Wistuba, The University of Texas MD Anderson Cancer Center, Houston, TX
    • Decoding the signaling circuitry of lung cancer through integrated genomics and proteomics
      John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Concurrent Session 2: RAS
    Session Chairperson: Garth Powis, Sanford-Burnham Medical Research Institute, La Jolla, CA
    • Targeting MEK alone or in combination in KRAS mutant lung cancer
      Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
    • New approaches to targeting RAS
      Tina Yuan, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
    • Building combination therapy for KRAS-driven lung cancer
      David A. Barbie, Dana-Farber Cancer Institute, Boston, MA
    • Novel targets for attacking RAS
      Garth Powis

Concurrent Sessions 3-4

4:45 p.m.-6:45 p.m.

  • Concurrent Session 3: Advances in Immunotherapy
    Session Chairperson: Roy S. Herbst, Yale Cancer Center, New Haven, CT
    • Oncology meets immunology: The cancer-immunity cycle and lung cancer
      Daniel Chen, Genentech Inc., South San Francisco, CA
    • Early but promising data: PD-1 inhibitors in non-small cell lung cancer
      Edward Garon, University of California, Los Angeles, CA
    • Clinical development of PDL1 antibodies in lung cancer
      Leora Horn, Vanderbilt-Ingram Cancer Center, Nashville, TN
    • Future directions for immunotherapy in NSCLC: Early-stage disease, drug combinations, and immunological monitoring
      Roy S. Herbst
  • Concurrent Session 4: Animal Models
    Session Co-Chairpersons: Katerina A. Politi, Yale Cancer Center, New Haven, CT, and Kwok-Kin Wong, Dana-Farber Cancer Institute, Boston, MA
    • Linking tumor genomics to patient outcomes through a large-scale patient-derived xenograft (PDX) platform
      David R. Gandara, UC Davis Comprehensive Cancer Center, Sacramento, CA
    • Developing a new functional classification of lung cancer based on tumor acquired vulnerabilities
      John D. Minna, UT Southwestern Medical Center, Dallas, TX
    • Mechanisms of sensitivity and resistance to EGFR-directed therapies in lung cancer models
      Katerina A. Politi
    • New genetic engineered mouse lung cancer models for pre- and co-clinical studies
      Kwok-Kin Wong

 

Wednesday, January 8

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 3: Lung Cancer Screening and Prevention

Session Co-Chairpersons: Denise R. Aberle, UCLA David Geffen School of Medicine, Los Angeles, CA, and Elda Railey, Research Advocacy Network, Plano, TX
8:00 a.m.-10:00 a.m.

Beyond efficacy: Implementing lung cancer screening
Denise R. Aberle

The management of screening-detected indeterminate pulmonary nodules
Pierre P. Massion, Vanderbilt University Medical Center, Nashville, TN

Airway transcriptome profiling for the early detection of lung cancer
Avrum E. Spira, Boston University School of Medicine, Boston, MA

Clinical utility of plasma-based microRNA signature classifier within computed tomography lung cancer screening
Gabriella Sozzi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Break

10:00 a.m.-10:30 a.m.

Plenary Session 4: EGFR Mutants in Lung Cancer: A 10-Year History

Session Co-Chairpersons: Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA, and William Pao, Vanderbilt University, Nashville, TN
10:30 a.m.-12:30 p.m.

Our expert speakers in this 10-year anniversary session will highlight this important finding in the study of lung cancer genomics. Dr. Lynch will provide a historical overview of the past 10 years and Dr. Mok will comment on the impact this discovery has made in the research and treatment of lung cancer. Dr. Yano’s talk will discuss the mechanisms of resistance to EFGR TKIs, while Dr. Pao will look ahead at new treatment strategies. The session will conclude with a discussion of the still unanswered questions we continue to research 10 years later.

Introduction
William Pao

EGFR mutated NSCLC: Response, resistance, and progress 10 years later
Thomas J. Lynch, Yale Cancer Center, New Haven, CT

EGFR mutants in lung cancer: A 10-year history
Tony S. K. Mok, Chinese University of Hong Kong, Hong Kong, China

Mechanisms of EGFR-TKI resistance in EGFR mutant lung cancer and its therapeutic strategy
Seiji Yano, Kanazawa University Cancer Research Institute, Kanazawa, Japan

New treatment strategies in EGFR mutant lung cancer
William Pao

Session Discussion and Unanswered Questions in 2014
Pasi A. Jänne

Poster Session B / Lunch

12:30 p.m.-2:30 p.m.

Mid-Conference Keynote Session

Session Co-Chairpersons: Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA, and William Pao, Vanderbilt University, Nashville, TN
2:30 p.m.-3:50 p.m.

Introduction

Somatic alterations in human cancer genomes
Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA

Keynote Discussion

Perspective
Natalie DiMarco, Penngrove, CA

Patients Powering Progress and Providing Solutions

3:50 p.m.-4:30 p.m.
Session Chairpersons: Bonnie J. Addario, Bonnie J. Addario Lung Cancer Foundation, San Carlos, CA, and Elda Railey, Research Advocacy Network, Plano, TX

Speakers:

Bonnie J. Addario

Elda Railey

Emily Bennett Taylor, Woodland Hills, CA 

Plenary Session 5:  Mechanisms of Drug Resistance

Session Co-Chairpersons: Robert C. Doebele, University of Colorado Denver, Aurora, CO, and Seiji Yano, Kanazawa University Cancer Research Institute, Kanazawa, Japan
4:45 p.m.-6:45 p.m.

Mechanism-based targeted polytherapy to enhance responses in lung cancer
Trever G. Bivona, University of California, San Francisco, CA

Overcoming resistance in ALK- and ROS1-positive NSCLC
Alice T. Shaw, Massachusetts General Hospital Cancer Center, Boston, MA

Treatment strategies to overcome EGFR TKI resistance
Myung-Ju Ahn, Sungkyunkwan University Samsung Medical Center, Seoul, South Korea

Title to be announced
Jeffrey Engelman, Massachusetts General Hospital, Boston, MA

 

Thursday, January 9

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 6: Short Talks from Highly Rated, Hot-Topic Abstracts

Session Co-Chairpersons: David H. Harpole, Duke University Medical Center, Durham, NC, and Alice Shaw, Massachusetts General Hospital Cancer Center, Boston, MA
8:00 a.m.-10:00 a.m.

Recurrent oncogenic mutations in the small GTPase RIT1 activate PI3K and MEK
Alice H. Berger, Broad Institute, Cambridge, MA

Comprehensive genomic characterization of lung adenocarcinoma by The Cancer Genome Atlas investigators (TCGA)
Eric Collisson, University of California, San Francisco, CA

Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms
Jaseok Peter Koo, Yale School of Medicine, New Haven, CT

Distinctive squamous cell carcinoma protein signatures
Rachel Ostroff, SomaLogic, Boulder, CO

Identification of functionally relevant off-targets of tivantinib in lung cancer
Uwe Rix, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

The neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis
Kerstin Sinkevicius, Boston Children’s Hospital, Boston, MA

BRG1-inactivating mutations as potential predictive markers for Aurora kinase A-targeted therapy
Vural Tagal, University of Texas (UT) Southwestern Medical Center, Dallas, TX

Pro-surfactant protein B as a biomarker for lung cancer prediction
Ayumu Taguchi, The University of Texas MD Anderson Cancer Center, Houston, TX

Break

10:00 a.m.-10:15 a.m.

Plenary Session 7: Advances in Molecular Targets and Novel Pathway-Based Therapy

Session Co-Chairpersons: David P. Carbone, The Ohio State University Comprehensive Cancer Center, Columbus, OH, and Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA
10:15 a.m.-12:15 p.m.

LKB1 loss induces characteristic pathway activation in human tumors and confers sensitivity to MEK inhibition associated with decreased PI3K-Akt-FOXO3 signaling
David Carbone

Squamous cell lung cancer 2014
Peter S. Hammerman, Dana-Farber Cancer Institute, Boston, MA

Novel pathway-based therapy for non-small cell lung cancer
Bruce E. Johnson

A new TRacK in lung cancer: NTRK1 gene fusions as a therapeutic target
Robert C. Doebele, University of Colorado Denver, Aurora, CO